Erciyes University Faculty of Health Sciences

Sponsor
TC Erciyes University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06156930
Collaborator
TUBİTAK (Other)
75
1
3
5.3
14.2

Study Details

Study Description

Brief Summary

Sleep disorders are important to place among the symptoms frequently seen in hemodialysis patients. Among sleep disorders, restless legs syndrome is the most common. Restless legs syndrome, seen in patients receiving hemodialysis treatment, causes excessive daytime sleepiness and negatively affects the sleep quality of individuals.

Condition or Disease Intervention/Treatment Phase
  • Other: Intervention group
  • Other: Placebo group
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
three-armedthree-armed
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
double-blind study design
Primary Purpose:
Supportive Care
Official Title:
Erciyes University Faculty of Health Sciences
Anticipated Study Start Date :
Nov 27, 2023
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
May 6, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group Lavander

The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.

Other: Intervention group
The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.
Other Names:
  • Lavender oil
  • Placebo Comparator: Placebo group sesame

    The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.

    Other: Placebo group
    The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
    Other Names:
  • Sesame oil
  • No Intervention: Control group

    Group of individuals receiving HD treatment who do not receive any treatment other than standard treatment

    Outcome Measures

    Primary Outcome Measures

    1. RLS Severity Rating Scale [Change compared to the initial score 1 month after aromatherapy massage application]

      The RLS Severity Rating Scale was developed in 2003. The scale was applied in the selection of patients and in the weekly evaluation of RLS severity. The scale comprised ten questions; each question was scored between 0 and 4. Questions 1, 2, 4, 6, 7, and 8 were related to RLS symptoms, questions 5, 9, and 10 were related to the effect of the disease on the mental state and daily social activities of patients with RLS, and question 3 was about the diagnostic criteria of RLS. The overall score indicated the RLS severity. A minimum score of 0 and a maximum score of 40 could be obtained. A score between 1 and 10 corresponded to "mild," 11-20 "moderate," 21-30 "severe," and 31-40 "very severe" RLS.

    2. Epworth Sleepiness Scale [Change compared to the initial score 1 month after aromatherapy massage application]

      Daytime sleepiness is determined with the scale developed in 1991. The scale consists of 8 questions in total and a high score from the scale indicates an increased level of daytime sleepiness. With this four-point Likert type scale, each question is rated between 0-3. In the evaluation of the scale; 0-5 points: normal, 6-10 points: normal but increased daytime sleepiness, 11-12 points: increased moderate daytime sleepiness, 13-15 points: increased moderate daytime sleepiness, 16-24 points: increased severe daytime sleepiness It is considered as sleepiness. The minimum score is 0, the maximum score is 24, and a total score of 11 or above indicates excessive daytime sleepiness of individuals.

    Secondary Outcome Measures

    1. Pittsburg Sleep Quality Index (PSQI) [Change compared to the initial score 1 month after aromatherapy massage application]

      PSQI is a reliable and valid index that measures sleep quality. The total score in the PSQI, which consists of 24 items and is divided into 7 sections (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disorder, use of sleeping pills and daytime dysfunction), varies between 0-21, and the PSQI total score is 5 and below. A score above 5 indicates that the sleep quality is 'good', and a score above 5 indicates that the sleep quality is 'bad'.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Those who are 18 years or older,

    • Not pregnant and not planning a pregnancy,

    • Having been diagnosed with restless leg syndrome according to the restless leg syndrome diagnostic scale and by a physician,

    • Having at least mild restless leg syndrome according to the restless leg syndrome severity rating scale,

    • Scoring 11 or above on the Epworth sleepiness scale,

    • PSQI score an average of 5 and above,

    • Receiving hemodialysis treatment in hemodialysis units for at least 3 months and 3 sessions per week,

    • Continuing dialysis treatment in the same institution,

    • Able to walk independently,

    • No changes in the treatment program before the massage and throughout the research process,

    • Not having any allergies to the oils to be used,

    • Individuals who can understand and communicate with Turkish will be included in the research

    Exclusion Criteria:
    • Those who are sensitive and/or have any allergies to the lavender oil to be used,

    • Those who have lower leg problems that would prevent them from applying massage to the lower leg area,

    • Have a history of mental or physical disability, including peripheral neuropathy, vascular problems in the legs,

    • Epilepsy, Alzheimer's, Parkinson's, Multiple Sclerosis, etc. Those with a diagnosed neurological disease such as

    • Pre-implemented,

    • Those with respiratory system disorders,

    • Patients who used other complementary and integrative therapies methods during the study period will be excluded from the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Internal Nursing, Faculty of Health Science, Erciyes University Kayseri Türkiye Turkey 38039

    Sponsors and Collaborators

    • TC Erciyes University
    • TUBİTAK

    Investigators

    • Principal Investigator: AYSER DÖNER, TC Erciyes University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ayser DÖNER, Research assistant (Principal Investigator), TC Erciyes University
    ClinicalTrials.gov Identifier:
    NCT06156930
    Other Study ID Numbers:
    • Erciyes University Health
    First Posted:
    Dec 5, 2023
    Last Update Posted:
    Dec 5, 2023
    Last Verified:
    Dec 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ayser DÖNER, Research assistant (Principal Investigator), TC Erciyes University

    Study Results

    No Results Posted as of Dec 5, 2023